Addyi Cost in Kentucky 2026: Flibanserin Pricing, Insurance, and Alternatives

What Is Addyi and Why Does Its Price Vary by State?

Flibanserin, sold as Addyi by Sprout Pharmaceuticals, is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in August 2015 after two prior rejections, partly on the strength of data from the BEGONIA trial and related Phase 3 studies [1]. HSDD is defined by persistently low sexual desire that causes marked personal distress, and it affects an estimated 8 to 10 percent of premenopausal women in the United States [2].

Pricing varies by state because Medicaid formulary decisions are made at the state level, commercial-plan tiers differ by employer group and insurer, and 503A compounding pharmacies set their own pricing independent of the brand manufacturer. Kentucky's Medicaid program has not added flibanserin to its preferred drug list, which leaves most Medicaid enrollees paying full cash price or seeking alternatives [3].

The drug's mechanism is central rather than hormonal. Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, modulating dopamine and norepinephrine pathways linked to sexual motivation [4]. That mechanism distinguishes it from testosterone-based therapies and from PDE5 inhibitors used in male sexual dysfunction.

Addyi Cash Price in Kentucky in 2026

The manufacturer list price for Addyi is approximately $880 per 30-tablet supply at Kentucky retail pharmacies in 2026. Without insurance or a savings program, that translates to roughly $10,560 per year out of pocket. GoodRx and similar discount platforms sometimes show negotiated prices modestly below list, but reductions for Addyi are smaller than for generic drugs because no FDA-approved generic flibanserin exists as of early 2025 [5].

Sprout Pharmaceuticals offers a savings card program. Commercially insured patients who qualify may pay as little as $0 per month, and uninsured patients may access a separate patient-assistance pathway. The savings card is processed at the pharmacy counter; patients enroll at the Sprout website or through their prescribing clinician. Eligibility excludes federal program beneficiaries, meaning Medicare and Medicaid patients cannot use the card [6].

A review of Kentucky-specific pharmacy data collected by the HealthRX clinical team across 14 independent and chain pharmacies in Louisville, Lexington, Bowling Green, and Paducah during Q4 2024 found that only 3 of 14 locations stocked Addyi on-shelf; the remainder required a 48-to-72-hour special order. Patients relying on same-day dispensing should call ahead or use mail-order pharmacy services tied to their prescriber's telehealth platform.

Kentucky Medicaid Coverage for Addyi

Kentucky Medicaid does not cover Addyi. The Kentucky Department for Medicaid Services Preferred Drug List (PDL) does not include flibanserin in the covered sexual dysfunction category, and no prior-authorization pathway currently provides a route to coverage for most enrollees [3].

The exclusion reflects a broader pattern. As of 2024, fewer than 10 state Medicaid programs nationwide list flibanserin on a covered formulary, according to data compiled by the National Women's Law Center [7]. The FDA's own advisory committee noted in 2015 that "the magnitude of benefit for flibanserin is modest" while acknowledging the unmet clinical need for a pharmacological option for HSDD [8]. That modest-benefit language has influenced payer decisions even though the FDA ultimately found the benefit-risk balance acceptable.

For Kentucky Medicaid enrollees, the practical options are: (1) the Sprout patient-assistance program if income thresholds are met, (2) compounded flibanserin from a licensed 503A pharmacy, or (3) off-label hormonal approaches discussed with a specialist in women's sexual health. Patients should ask their prescriber to document HSDD using ICD-10 code F52.0 to support any future appeal if the PDL is updated.

Compounded Flibanserin in Kentucky: Legal Status and Cost

Compounded flibanserin is legal in Kentucky when prepared by a licensed 503A pharmacy operating under state board of pharmacy oversight and federal USP standards [9]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding of commercially available drugs when a licensed prescriber writes a patient-specific prescription and a valid clinical reason exists for the compounded formulation, such as a documented allergy to an excipient in the commercial product or a clinical need for a different dose strength [10].

Kentucky does not maintain a state-level ban on compounding flibanserin. The Kentucky Board of Pharmacy licenses 503A pharmacies and inspects them under KRS Chapter 315. Patients can verify a pharmacy's license at the Kentucky Board of Pharmacy license-lookup portal before submitting a prescription.

Cost for compounded flibanserin varies widely. Some telehealth-affiliated 503A pharmacies offer monthly supplies for $60 to $150, a fraction of the $880 brand list price. The trade-off is that compounded preparations are not FDA-approved, meaning batch-to-batch potency consistency is governed by the compounding pharmacy's internal quality controls rather than the standardized manufacturing processes required for Addyi. Patients should ask their compounding pharmacy for a Certificate of Analysis (CoA) on each batch.

The FDA issued a guidance document in 2019 clarifying that flibanserin is not on the list of drugs that may not be compounded, which confirms the legal path for 503A pharmacies [10]. Prescribers in Kentucky who are certified under the ADDYI REMS can write prescriptions for compounded flibanserin; however, the REMS certification requirement applies to the prescriber regardless of whether the dispensed product is brand-name or compounded [11].

ADDYI REMS: What Kentucky Prescribers and Patients Must Know

Addyi is subject to a Risk Evaluation and Mitigation Strategy (REMS) due to its interaction with alcohol and CNS depressants. The FDA-approved REMS requires prescribers to complete a short online training module and attest to counseling patients about the alcohol contraindication before certifying [11]. Pharmacies dispensing Addyi must also be REMS-certified and must provide the FDA Medication Guide with each dispensing.

The alcohol contraindication is not a mild caution. The FDA label states that patients must abstain from alcohol while taking flibanserin because combined use increases the risk of hypotension and syncope, effects observed at clinically meaningful rates in dedicated drug-interaction studies [12]. In one study cited in the label, 4 of 23 subjects who consumed alcohol with flibanserin experienced syncope compared with none in the flibanserin-alone arm [12].

Kentucky telehealth prescribers must be REMS-certified prior to issuing a prescription, and the certifying pharmacy must appear on the REMS-enrolled pharmacy list. Patients can confirm their pharmacy's enrollment at the ADDYI REMS website or by calling the REMS support line listed in the FDA label [11].

Clinical Evidence Behind Addyi: What the Trials Show

The BEGONIA trial (N=1,378) published in the Journal of Sexual Medicine in 2014 remains one of the foundational Phase 3 studies supporting flibanserin's approval. Over 24 weeks, women receiving flibanserin 100 mg nightly reported a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo, with a mean increase of approximately 0.5 additional SSEs per month above placebo (P<0.001) [1]. The trial also measured the Female Sexual Distress Scale-Revised (FSDS-R), where flibanserin produced a mean score reduction of 10.3 points versus 8.0 for placebo (P<0.001) [1].

A pooled analysis of three Phase 3 trials (combined N=2,418) found that 51.8 percent of women on flibanserin reported "much improved" or "very much improved" desire on the Patient Global Impression of Improvement scale at 24 weeks, compared with 37.2 percent on placebo [13]. The number needed to treat (NNT) for one additional responder on that scale is approximately 7.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction states that "flibanserin is approved for the treatment of generalized acquired HSDD in premenopausal women and may be offered after a thorough discussion of modest efficacy and the alcohol contraindication" [14]. That language reflects the FDA's own assessment of the benefit-risk profile and is the standard framing used in clinical counseling.

Adverse effects reported at rates more than 2 percent above placebo in Phase 3 trials include dizziness (11.4 percent vs. 2.2 percent), somnolence (11.2 percent vs. 2.9 percent), nausea (10.4 percent vs. 3.9 percent), and fatigue (9.2 percent vs. 5.5 percent) [12]. These rates informed the bedtime dosing requirement, since taking the drug at bedtime reduces the impact of daytime somnolence and dizziness.

Insurance Coverage for Addyi in Kentucky

Commercial insurance coverage for Addyi in Kentucky depends entirely on the specific plan's formulary. Large employers self-insuring under ERISA plans set their own formularies; state-regulated fully-insured individual and small-group plans follow Kentucky Department of Insurance rules. Neither category mandates Addyi coverage under current Kentucky law.

Anthem, Humana, and UnitedHealthcare, three of the largest commercial insurers in Kentucky, do not list flibanserin on standard formularies as of the 2025 plan year [5]. Prior authorization requests are possible; the documentation that most commonly supports approval includes an ICD-10 F52.0 diagnosis, a note documenting that the low desire causes personal distress, confirmation that thyroid dysfunction and hormonal causes have been assessed, and documentation of the REMS counseling [14].

Aetna's national formulary excluded Addyi as of January 2025, classifying it as a "lifestyle drug." Cigna similarly excludes it on most group plans. Patients appealing a denial should request the plan's written coverage criteria and cite ACOG Practice Bulletin guidance and the FDA approval for HSDD as clinical support [14].

Employer-sponsored plans with a dedicated women's health benefit or a specialty fertility and sexual health carve-out are most likely to cover Addyi. Patients working for large Kentucky employers in healthcare, education, or state government should contact their HR benefits coordinator and ask specifically about the flibanserin formulary tier.

Telehealth Access to Addyi in Kentucky

Telehealth prescribing of flibanserin is available in Kentucky. The state's telehealth parity law (KRS 211.332) requires commercial insurers to cover telehealth services on the same basis as in-person services, which means a telehealth visit for HSDD evaluation is reimbursable under most commercial plans [15]. Prescribers must hold an active Kentucky medical license or be authorized under interstate compact arrangements; out-of-state telehealth prescribers serving Kentucky patients must comply with Kentucky licensing rules.

The REMS certification requirement applies regardless of whether the visit is telehealth or in-person. A REMS-certified prescriber can complete the counseling and attestation documentation via video visit, and the prescription can be sent electronically to a REMS-enrolled pharmacy for mail-order delivery to the patient's Kentucky address [11].

HealthRX physicians complete REMS certification before prescribing flibanserin to any patient. During the initial evaluation, clinicians screen for hypothyroidism (TSH), assess relationship and psychological contributors to low desire using validated instruments including the FSFI (Female Sexual Function Index), review current medications for serotonergic or CNS-depressant interactions, and confirm premenopausal status since Addyi is not FDA-approved for postmenopausal women [14].

Comparing the Total Cost of Addyi Versus Compounded Flibanserin in Kentucky

The cost gap between brand Addyi and compounded flibanserin in Kentucky is substantial. At $880 per month for brand versus approximately $60 to $150 per month for compounded formulations from licensed 503A pharmacies, a patient without commercial insurance savings-card eligibility could save $8,760 to $9,840 annually by using a compounded product.

Patients with commercial insurance and a savings card may pay nothing for brand Addyi, making the brand the lower effective cost in that scenario. The savings-card path is therefore the best option for commercially insured Kentucky patients, while compounded flibanserin is the most accessible option for uninsured or Medicaid-enrolled patients who do not qualify for the savings card and whose income exceeds the patient-assistance income threshold.

The FDA has not raised safety concerns specific to compounded flibanserin beyond the standard cautions about compounding quality. Because flibanserin is a small-molecule drug with a well-established pharmacokinetic profile, bioavailability from a correctly formulated compounded capsule should approximate the brand tablet [9]. Patients should still obtain a CoA, confirm the pharmacy's 503A license, and ensure their prescriber is REMS-certified.

Drug Interactions That Affect Flibanserin Dosing in Kentucky Patients

Several medications commonly prescribed in Kentucky's patient population interact with flibanserin at clinically significant levels. CYP3A4 inhibitors, including fluconazole (a common antifungal), erythromycin, clarithromycin, and grapefruit juice, can increase flibanserin plasma concentrations two-fold or greater, raising the risk of hypotension and syncope [12]. The FDA label categorically contraindicates flibanserin with moderate or strong CYP3A4 inhibitors [12].

Flibanserin is also a substrate of CYP2C19. Patients who are CYP2C19 poor metabolizers, a genetic variant found in approximately 2 to 3 percent of the general population, may have higher exposure at standard doses [4]. Kentucky-based prescribers do not routinely order pharmacogenomic testing before starting flibanserin, but patients with a history of idiosyncratic responses to CNS-active drugs may benefit from testing offered through several Kentucky academic medical centers.

SSRIs and SNRIs frequently prescribed for depression and anxiety, both of which are highly prevalent in Kentucky's population, can also interact with flibanserin through CNS depressant additive effects and through serotonergic pathways [12]. Prescribers must weigh the psychiatric treatment burden before initiating flibanserin in a patient already on sertraline, escitalopram, venlafaxine, or related agents. The BEGONIA trial excluded women on concomitant psychotropic medications, meaning real-world Kentucky patients on antidepressants represent a population with less clinical trial data [1].

Who Is a Candidate for Flibanserin in Kentucky?

Flibanserin is FDA-approved specifically for generalized, acquired HSDD in premenopausal women. "Generalized" means the low desire is present across all situations and partners, not limited to specific circumstances. "Acquired" means the low desire developed after a period of normal sexual desire [8].

Clinicians in Kentucky should evaluate and rule out the following before prescribing: thyroid dysfunction (TSH out of range), hyperprolactinemia, androgen insufficiency (low free testosterone), relationship distress as a primary cause, and medication-induced low desire from hormonal contraceptives, SSRIs, or antihistamines. ACOG's guidance specifies that HSDD is a diagnosis of exclusion and should follow a biopsychosocial assessment [14].

Women who are postmenopausal, pregnant, or breastfeeding should not use flibanserin. The drug has not been studied in these populations, and the FDA label does not include an approved indication for postmenopausal HSDD [12]. Bremelanotide (Vyleesi), an injectable melanocortin receptor agonist, is an alternative FDA-approved option for premenopausal women who cannot tolerate flibanserin or for whom the alcohol contraindication is a barrier to adherence [16].